转移性去势抵抗性前列腺癌串联治疗中循环肿瘤DNA动态的探索性病例系列
该探索性病例系列纳入接受锕-镥串联PSMA靶向放射配体治疗的转移性去势抵抗性前列腺癌患者,采用超低覆盖度全基因组测序(ULP-WGS)和ichorCNA估算循环肿瘤DNA肿瘤分数(TFx),并与PSA及影像纵向比较。4例患者中TFx动态可早于PSA反映治疗反应与耐药,提示其可能补充PSMA影像以指导个体化治疗决策。
要点
- 连续ctDNA肿瘤分数动态可早期识别锕-镥串联治疗的反应与耐药。
- 部分患者TFx升高早于PSA复发,提示可更早发现疾病进展。
- TFx动态可能补充PSMA影像,辅助及时调整个体化治疗。
核心结论
- 纵向ctDNA肿瘤分数动态可早期检测mCRPC对锕-镥串联治疗的反应和耐药,并可能补充PSMA影像以指导及时、个体化的治疗决策。
研究设计与样本
- 探索性病例系列,纳入接受锕-镥([225Ac]Ac-PSMA-617与[177Lu]Lu-PSMA-617)串联治疗的mCRPC患者,每两月采集血样。
- 提取游离DNA并以≤7×覆盖度的ULP-WGS分析,用ichorCNA估算肿瘤分数,并与PSA及影像数据纵向比较。
主要发现
- 患者1经两周期治疗后达到完全缓解,PSA与TFx均不可测。
- 患者2治疗反应强而持久,但在长期治疗中断后ctDNA分析发现基因组进展,而PSA水平稳定。
- 患者3初期有治疗反应,但第三周期TFx开始升高并早于PSA复发,提示早期疾病进展。
- 患者4被归类为无应答者,仅见短暂TFx下降,第二周期时PSA与TFx已升高并快速疾病进展。
关键数值与推荐
- cfDNA采用ULP-WGS分析,测序覆盖度≤7×。
- TFx由ichorCNA从ULP-WGS数据估算。
- 血样采集频率为每两月一次。
临床怎么用
- 在锕-镥串联治疗期间可纵向监测ctDNA肿瘤分数,结合PSA与PSMA影像综合判断疗效与耐药。
- 对TFx升高而PSA稳定或治疗中断的患者,应警惕基因组进展并考虑早期影像或治疗调整。
局限性
- 原文为探索性病例系列,样本量小,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) with the alpha-emitter actinium-225 (225Ac) has shown promising activity in metastatic castration-resistant prostate cancer (mCRPC), but its use is limited by toxicity. A tandem approach combining [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 (actinium-lutetium) has been developed to mitigate adverse effects and optimize efficacy. Given the scarcity of 225Ac and the emergence of resistance, early identification of non-responders is crucial. Circulating tumor DNA (ctDNA), especially tumor fraction (TFx) estimated from ultra-low-pass whole genome sequencing (ULP-WGS) using ichorCNA, may provide a non-invasive biomarker for monitoring treatment response. Blood samples were collected from mCRPC patients treated with actinium-lutetium bimonthly. Cell-free DNA (cfDNA) was extracted and analyzed by ULP-WGS (≤ 7 × coverage). TFx was derived using ichorCNA and compared longitudinally with prostate-specific antigen (PSA) and imaging data. RESULTS: Patient 1 achieved complete remission with undetectable PSA and TFx after two cycles. Patient 2 showed a strong and sustained therapeutic response; however, after a prolonged treatment hiatus, ctDNA analysis detected genomic progression despite stable PSA levels. Patient 3 initially responded to therapy, but TFx began rising during the third cycle, preceding PSA relapse, indicating early disease progression. Patient 4, classified as a non-responder, showed only transient TFx reduction and experienced rapid disease progression, with increasing PSA and TFx levels already by the second cycle. CONCLUSIONS: Longitudinal ctDNA TFx dynamics enable early detection of response and resistance to actinium-lutetium in mCRPC and may complement PSMA imaging to guide timely, personalized treatment decisions.
引用
- Amghar M, Rausch T, Özgür H, et al. Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer. EJNMMI Res. 2026. PMID: 41670929. doi:10.1186/s13550-026-01388-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。